-
Rheumatology: The effect of fegotinib on the structural damage of sacroiliac joint MRI at 12 weeks in patients with active ankylosing spondylitis (Tortuga test
Time of Update: 2021-11-03
Rheumatology (Oxford) 2021 Aug 05Maksymowych WP, Østergaard M, Landewé R , Impact of filgotinib on sacroiliac joint MRI structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial) .
-
The composition and preparation steps of the two lysates
Time of Update: 2020-10-20
related topics . The components of cytolytic lysate include Tris-HCl, EDTA and NaCl. the lysate are mainly Urea, thiourea, CHAPS, etc. In addition to protein extraction lysate, the use of these
-
Study on Synthesis of Hybrid Polyester Resin for Indoor Thermal Transfer Powder Coatings
Time of Update: 2020-10-09
From Table 3 and Figure 2, it can be known that under the premise of controlling the final acid value of polyester, the addition of EG has little effect on the performance of the coating thermal transfer tear paper, nor does it significantly affect the melting viscosity of polyester and the glassification transition temperature (Tg), even if the EG replaces 50% NPG, the molten viscosity of the resin and Tg are not much different.
-
Keytruda has been approved for the first PD-1 treatment for NMIBC
Time of Update: 2020-08-01
On January 8, local time, the U.S. FDA announced the approval of Mercato's PD-1 inhibitor Keytruda (pembrolizumab) as a single drug therapy for specific high-risk non-muscle-immersed bladder cancer (NMIBC) patients, specifically: non-qualified bladder removal or have chosen not to have a bladder removal of the catonic seedlings without response, high risk, associated with insituated cancer (CIS), companion or non-cosmic nipple lesions.
-
Lilly's REYVOW is the first and only new type of acute migraine treatment that is now available for prescription in the United States
Time of Update: 2020-06-21
Lilly announced today that REYVOW (Iasmiditan) C-V 50 mg and 100 mg tablets for acute treatment of adult patients with or without preeclampsia can now be prescribed and available at pharmacies in th
-
Sanofi's Plavix withdraws from the bidding for essential drugs in Shaanxi Province (I
Time of Update: 2013-07-02
Source: FDC pharmasia news 2013-7-2 Beijing - Sanofi has decided to withdraw from the bidding for essential drugs in Shaanxi Province after the price of clopidogrel, the best-selling product, has been
